SERCAP: is the perfect the enemy of the good?
Abstract Single Encounter Radical Cure and Prophylaxis (SERCAP) describes an ideal anti-malarial drug that cures all malaria in a single dose. This target product profile has dominated anti-malarial drug discovery and development over the past decade. The operational advantage of a single encounter...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-06-01
|
| Series: | Malaria Journal |
| Online Access: | https://doi.org/10.1186/s12936-021-03821-z |
| id |
doaj-b98b1c0c5aae4839ab7e69a32365be0b |
|---|---|
| record_format |
Article |
| spelling |
doaj-b98b1c0c5aae4839ab7e69a32365be0b2021-06-27T11:46:09ZengBMCMalaria Journal1475-28752021-06-012011410.1186/s12936-021-03821-zSERCAP: is the perfect the enemy of the good?Nicholas J. White0François H. Nosten1Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol UniversityCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of OxfordAbstract Single Encounter Radical Cure and Prophylaxis (SERCAP) describes an ideal anti-malarial drug that cures all malaria in a single dose. This target product profile has dominated anti-malarial drug discovery and development over the past decade. The operational advantage of a single encounter has to be balanced against the need for a high dose, reliable absorption, little variability in pharmacokinetic properties, slow elimination (to ensure curative drug exposures in all patients) and a very low rate of vomiting. The demanding aspirational target may have hindered anti-malarial drug development. Aiming for three-day regimens, as in current anti-malarial treatments, would be better.https://doi.org/10.1186/s12936-021-03821-z |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Nicholas J. White François H. Nosten |
| spellingShingle |
Nicholas J. White François H. Nosten SERCAP: is the perfect the enemy of the good? Malaria Journal |
| author_facet |
Nicholas J. White François H. Nosten |
| author_sort |
Nicholas J. White |
| title |
SERCAP: is the perfect the enemy of the good? |
| title_short |
SERCAP: is the perfect the enemy of the good? |
| title_full |
SERCAP: is the perfect the enemy of the good? |
| title_fullStr |
SERCAP: is the perfect the enemy of the good? |
| title_full_unstemmed |
SERCAP: is the perfect the enemy of the good? |
| title_sort |
sercap: is the perfect the enemy of the good? |
| publisher |
BMC |
| series |
Malaria Journal |
| issn |
1475-2875 |
| publishDate |
2021-06-01 |
| description |
Abstract Single Encounter Radical Cure and Prophylaxis (SERCAP) describes an ideal anti-malarial drug that cures all malaria in a single dose. This target product profile has dominated anti-malarial drug discovery and development over the past decade. The operational advantage of a single encounter has to be balanced against the need for a high dose, reliable absorption, little variability in pharmacokinetic properties, slow elimination (to ensure curative drug exposures in all patients) and a very low rate of vomiting. The demanding aspirational target may have hindered anti-malarial drug development. Aiming for three-day regimens, as in current anti-malarial treatments, would be better. |
| url |
https://doi.org/10.1186/s12936-021-03821-z |
| work_keys_str_mv |
AT nicholasjwhite sercapistheperfecttheenemyofthegood AT francoishnosten sercapistheperfecttheenemyofthegood |
| _version_ |
1721357566453219328 |